Version May 2024
Varicose veins:
Note: A test dose of 0.25 to 1 mL may be injected into a varicosity 24 hours before full-dose treatment.
Full-dose treatment: Note: Dose dependent on the size and degree of varicosity; may be given as multiple injections at one time as a single dose.
Small or medium veins: IV: 50 to 100 mg (1 to 2 mL).
Large veins: IV: 150 to 250 mg (3 to 5 mL).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Frequency not defined:
Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)
Local: Local discomfort (cramping), localized burning
Postmarketing: Cardiovascular: Pulmonary embolism, thrombosis
Hypersensitivity to morrhuate sodium or any component of the formulation; arterial disease; acute thrombophlebitis; valvular or deep vein incompetence; varicosities caused by abdominal or pelvic tumors; patients with systemic diseases (eg, uncontrolled diabetes mellitus, thyrotoxicosis, tuberculosis, neoplasms, asthma, sepsis, blood dyscrasias, and acute respiratory or skin diseases); acute local or systemic infection (including infected ulcers); continued administration following a systemic reaction or an unusual local reaction at the injection site; extensive therapy in severely debilitated, bedridden, or senile patients.
Concerns related to adverse effects:
• Anaphylactic/hypersensitivity reactions: Anaphylactic and hypersensitivity reactions (eg, asthma, nausea, vomiting, respiratory depression, urticaria, vascular collapse) have occurred. Immediate treatment (including epinephrine, antihistamines, corticosteroids) should be available.
• Extravasation: Sloughing and necrosis of tissue may occur following extravasation.
• Local reactions: Burning or cramping sensations may occur following administration.
• Thromboembolism: Thrombosis and subsequent deep vein thrombosis and pulmonary embolism may occur following treatment.
Dosage form specific issues :
• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.
Special populations:
• Debilitated patients: Not recommended in patients who are severely debilitated or senile.
Other warnings/precautions:
• Experienced physician: This drug should only be administered by a physician familiar with proper injection techniques.
Yes
Solution (Scleromate Intravenous)
5% (30 mL): $104.83
Disclaimer: The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.
IV: For IV injection into varicose vein only; avoid extravasation. Use only clear solution; solution should become clear when warmed. Do not use if solid does not dissolve completely upon warming. Solution froths easily; use a large bore needle to fill syringe and a small bore needle for injection. If solution is cold or if the solid matter has separated in the solution, warm solution by immersing in hot water prior to injection into small vein.
Varicose veins: For obliteration of primary varicosed veins that consist of simple dilation with competent valves.
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted.
Prior to use, evaluate valvular competency and deep vein patency/competency by angiography and/or by clinical tests (eg, Trendelenburg, Perthes); hypersensitivity reactions and/or anaphylaxis; signs and symptoms of deep vein thrombosis or pulmonary embolism.
Morrhuate sodium causes inflammation of the vein's intima resulting in the formation of a thrombus. Occlusion secondary to the fibrous tissue and the thrombus results in the obliteration of the vein.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
